The Oral GLP-1 Revolution: How Foundayo Bests Injectable Semaglutide

The News

For years, GLP-1 receptor agonists have been the most talked-about class in metabolic health -- and almost exclusively as injectables. Semaglutide (Ozempic, Rybelsus) and tirzepatide (Mounjaro, Zepbound) have dominated the conversation, but until very recently, the idea of an oral GLP-1 that could match or exceed their efficacy felt more like wishful thinking than reality. That changed in June 2026, when Eli Lilly announced Phase 3 ACHIEVE program results demonstrating that its oral GLP-1 receptor agonist, Foundayo (generic name: orforglipron), outperforms injectable oral semaglutide across the board -- in head-to-head trials, in real-world comparisons, and against placebo added to background therapy.

The Data

The ACHIEVE-3 trial, presented at ADA's 86th Scientific Sessions, was the landmark head-to-head: 1,698 adults with type 2 diabetes inadequately controlled on metformin were randomized 1:1:1:1 to Foundayo 9 mg or 17.2 mg, or oral semaglutide 7 mg or 14 mg, for 52 weeks. Foundayo 17.2 mg drove a 57.1% greater relative reduction in A1C and a 73.6% greater relative weight loss compared to oral semaglutide 14 mg. At the 9-mg dose, Foundayo still held a significant edge: A1C reduction of 1.9% vs. 1.1% for semaglutide 7 mg, and weight loss of 14.6 lbs vs. 7.9 lbs.

What It Means

For people living with type 2 diabetes, Foundayo represents a new option with two significant advantages: superior efficacy (better A1C and weight loss than injectable semaglutide in head-to-head testing) and oral convenience (no injection, no food or water restrictions). For the broader GLP-1 landscape, Foundayo's success signals a potential shift in how GLP-1 therapies are developed and prescribed. The fact that a small molecule can outshoot a peptide-based GLP-1 RA in a head-to-head trial opens the door for more oral options in the future. For peptide-focused communities, this is also a reminder that the clinical end of the peptide world is being reshaped by small-molecule innovation -- though BPC-157, TB-500, and KPV still have their place in research contexts.

Oria Take

We called this one. Not because we predicted Foundayo specifically -- though the writing was on the wall when Lilly began dosing -- but because the trend toward oral GLP-1s has been building for years. Rybelsus proved there was a market for oral GLP-1, but its efficacy was modest compared to injectable semaglutide. Foundayo changes the math entirely. What's exciting here isn't just that a new drug works well -- it's that the delivery format changes the patient experience. For someone who's been hesitating to start injectable therapy, the oral option may be the nudge they need. For someone already on injectables, the prospect of switching to a once-daily pill with better outcomes is genuinely practice-changing. That said, we'd be remiss not to note the GI side-effect profile. Nausea and diarrhea are practically expected with any GLP-1, but the discontinuation rates suggest that not everyone tolerates the step-up approach. The titration protocol (starting low and moving up over 4-6 weeks) seems key, but real-world adherence to titration may vary. We also want to flag that this is a small-molecule drug, not a peptide. For the Oria community -- which has deep engagement with peptide research, from BPC-157 to TB-500 to KPV -- Foundayo represents a different category entirely. The mechanisms, development pathways, and even the side-effect profiles differ. That doesn't make one category better; it just means the choice may come down to what kind of therapeutic approach aligns with your health philosophy and practical needs. Bottom line: If you've been waiting for an oral GLP-1 that can match or beat injectable efficacy, the wait is over. Foundayo is here, the data are compelling, and the implications for how we think about metabolic-medication choices just got a lot more interesting.

Sources

• ACHIEVE-3 (NCT06045221): Phase 3, 52-week randomized open-label trial of Foundayo vs. oral semaglutide in T2D inadequately controlled on metformin. Presented at ADA 86th Scientific Sessions, June 2026. Lilly gcs-web.com press release, June 8, 2026.

• ACHIEVE-2 (NCT06192108): Phase 3, 40-week randomized active-controlled trial of Foundayo vs. dapagliflozin in T2D. Presented at ADA 86th Scientific Sessions, June 2026.

• ACHIEVE-5 (NCT06109311): Phase 3, 40-week randomized double-blind placebo-controlled trial of Foundayo vs. placebo + insulin glargine in T2D. Presented at ADA 86th Scientific Sessions, June 2026.

• Efficacy tables and quoted data from Lilly's ACHIEVE program press release and clinical trial results.

• FDA prescribing information for Foundayo (orforglipron), approved for adults with obesity or overweight with weight-related medical problems.

• PubMed abstracts: Sahu L et al. "Oral Versus Injectable Incretin-Based Anti-Obesity Therapies" (OMICS, 2026); Escudero Samaniego DG et al. "Adverse oral effects of GLP-1 and GIP receptor agonists" (BMJ Open, 2026); Jang R et al. "GLP-1-based therapies in cardiovascular disease" (Eur J Clin Pharmacol, 2026).